ESC 2026: Congress brings key readouts across the cardiovascular space
With the 2026 European Society of Cardiology (ESC) Congress in full swing, cardiologists and industry titans alike are gathering in …
Post
-
-
ESC 2026: enlicitide extends oral PCSK9 benefits beyond LDL-C lowering
This year at the European Society of Cardiology (ESC) Scientific Sessions, Phase III data were presented evaluating the Lipoprotein(a) [Lp(a)]-lowering …
-
ESC 2026: laroprovstat evaluated to close the LDL-C treatment gap
This year at the European Society of Cardiology (ESC) Scientific Sessions, preliminary Phase III data were presented from the ongoing …
-
Verrica completes enrolment in Phase III trial of Ycanth
Verrica Pharmaceuticals has completed patient enrolment in its first pivotal Phase III trial, COVE-2, which is part of a global …
-
First patient dosed in Daiichi Sankyo’s Phase I DS1025 study
Daiichi Sankyo has dosed the first patient in a Phase I clinical trial assessing DS1025 in adults with advanced or …
-
Amgen-AstraZeneca’s Tezspire nets another Phase III inflammatory disease win
Amgen and AstraZeneca’s co-developed blockbuster therapy Tezspire (tezepelumab) scored a Phase III win in a third epithelial-driven inflammatory disease – …
-
MicrobiotiX concludes sentinel cohort in Phase I trial of MP101
MicrobiotiX has completed the sentinel cohort of its Phase I, first-in-human clinical trial evaluating MP101 in adult patients with pneumonia …
-
HaemaLogiX doses first patient with KMCAR T-cell in KOALA trial
HaemaLogiX has treated the first patient with its KMCAR T-cell therapy as part of the Phase I KOALA clinical trial …
-
Akeso logs Phase III success in second tumour type for ivonescimab
Summit Therapeutics’ $500m upfront bet on Akeso’s PD-1 x VEGF bispecific, ivonescimab, is looking increasingly well placed, with the latter …
-
Airway Therapeutics secures $50m for Phase IIb/III zelpultide alfa trial
Airway Therapeutics has raised $50m in new equity financing to support its ongoing Phase IIb/III clinical trial of zelpultide alfa …
-
Patient enrolment concludes in Senhwa’s Phase Ib trial of pidnarulex
Senhwa Biosciences has completed enrolment in its Phase Ib expansion trial of pidnarulex (CX-5461) as a monotherapy for people with …
-
Bausch + Lomb progresses dry eye candidate to Phase III despite mixed data
Bausch + Lomb has chosen to advance two of its pharmaceutical assets further down the clinical pipeline, despite one of …
-
Surveillance and vaccine could protect against higher cancer risk from Lynch syndrome
In addition to cancer risk factors such as ageing, environmental risk factors, and lifestyle risk factors, family history of cancer …
-
Asia’s clinical research revolution: Why the world’s innovation centre is shifting east
The global map of clinical research is changing rapidly. Once viewed primarily as an attractive destination for cost-efficient clinical trials, …
-
Liminatus Pharma selects Synex to advance CAR-T trial
Liminatus Pharma has engaged Korean contract research organisation Synex Consulting to provide clinical research services for the Phase I/IIa study …
